Genedata Adds Integrated Electronic Lab Notebook to Its Biopharma R&D Platform

An ELN embedded in the R&D process

Genedata describes its new ELN as natively embedded in the R&D process, in contrast to traditional notebooks that run independently. It is designed to support end-to-end discovery and development workflows for biologics and other complex modalities, including ADCs, bispecifics, cell and gene therapies, and peptides.

The notebook builds on the data model Genedata already uses. It links directly to molecules, samples, process parameters, and assay and analytics results that are managed in the platform. According to the company, this reduces manual data transfers and removes inconsistencies between applications.

Experiment documentation stays tied to a candidate's full development history. Genedata lists the stages as design and molecular biology, screening, engineering, expression, purification, and analytics, followed by upstream and downstream process development, formulation, and analytical development. The aim is to give scientists and AI systems consistent, traceable data across the R&D lifecycle.

Connecting LIMS, samples and lab execution

The ELN links experiments to sample identities, properties, lineage, and physical locations. Integrated LIMS and laboratory workflow execution capabilities coordinate requests and tasks across internal laboratories, centralized facilities, CROs, and CDMOs.

Connections to laboratory and IT systems, instruments, and robotics are meant to cut manual data handling further and bring documentation closer to what happens at the bench. Genedata says that by combining ELN, LIMS, sample management, registration, and laboratory workflow execution across its platform, the ELN provides built-in data integrity while raising R&D efficiency.

The company also claims practical gains for organizations: historical work is easier to revisit, institutional knowledge is fully preserved, and project handovers are simplified.

Positioning for AI-driven research

Genedata frames the launch around AI readiness. Othmar Pfannes, Ph.D., President of Genedata, said that traditional ELNs "operate independently and cause knowledge to be fragmented." He said the company aligned underlying data structures, scientific concepts and metadata so information can be consistently searched, analyzed, reused, and used by AI applications.

Pfannes also said: "We are fundamentally rethinking what an ELN should be in the age of AI." According to him, combining structured data and workflows with experimental context in a single scientific record yields a harmonized user experience on a shared, computationally accessible foundation.

Genedata says this unified environment supports data science, predictive modeling, automation, and AI-driven initiatives without the cost and complexity of connecting fragmented systems.

What it means for biopharma teams

For R&D organizations that already use the Genedata platform, the release adds notebook functionality inside the same environment that holds their molecule, sample and assay data. Based on the company's description, the main benefit is a continuous scientific record rather than separate systems that must be reconciled by hand.

The announcement does not give pricing, availability details or performance figures. Genedata, which says it has been trusted by customers worldwide for more than 25 years, presents the ELN as a way to preserve knowledge and speed up decisions as biologics pipelines grow more complex.